Investor Overview

Corporate Profile

Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.

Featured Report

Stock Performance

3 mo. 6 mo. 1 yr.
Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

Upcoming Events

There are currently no events to display.

More Events

Print Page RSS Feeds Email Alerts IR Contacts

Developing novel therapeutics for the treatment of rare diseases.

Pages

Contact Us

  • 203 Redwood Shores Pkwy
  • Ste 500
  • Redwood City, CA 94065